Pilot study puts injectable BOAS therapy on the radar: full analysis
Version 2
A small pilot study is putting a new idea into the BOAS conversation: drug-based airway support instead of, or alongside, surgery. In a paper published in The Veterinary Journal, investigators described clinical observations in six British bulldogs treated with Snoretox-1, an injectable targeted neuromuscular stimulant that combines tetanus toxin with an immunological decoy. All six dogs reportedly improved by at least one Respiratory Function Grading level, and the observed effect lasted from 20 to 53 weeks. RMIT University and Melbourne-based Snoretox Ltd. announced the results on April 23, 2026, framing the therapy as an early, less-invasive option for flat-faced dogs with airway obstruction. (rmit.edu.au)
That matters because BOAS remains one of the clearest welfare issues in brachycephalic practice. The condition affects breathing, exercise tolerance, sleep, thermoregulation, and sometimes feeding, and it is common enough in bulldogs, French bulldogs, and pugs that noisy breathing is still too often normalized by pet parents and, at times, by professionals. The Cambridge/The Kennel Club Respiratory Function Grading Scheme is now a familiar framework for assessing these dogs, using pre- and post-exercise breathing noise and effort to distinguish clinically unaffected dogs from those with moderate or severe disease that need management or treatment. (vet.cam.ac.uk)
The new study’s treatment concept is unusual but straightforward in intent: improve tone in muscles that help support the upper airway. RMIT said Snoretox-1 is injected into the floor-of-mouth musculature to help keep the airway open. The study summary available online indicates British bulldogs were enrolled if they were at least 12 months old, had owner-reported BOAS history, an accredited veterinarian BOAS rating of at least 2, and an anti-tetanus antibody titer below a specified threshold. Dogs were monitored by pet parents daily and rechecked by veterinarians at 14 days, 28 days, and then about every four weeks. The reported target site was the rostral geniohyoid muscle. (rmit.edu.au)
The company and university are also leaning into a practical clinical message: this may not be only for surgery-naive dogs. In the RMIT release, Tony Sasse said the team observed improvement even in dogs that had not responded well to prior surgery. He also argued the findings suggest a possible combination with surgery, or an alternative in some cases. That framing is likely to resonate with clinicians who manage residual signs after nares and soft palate procedures, especially in dogs whose anatomy, weight, inflammation, or comorbidities make outcomes less predictable. Still, the current evidence is early-stage and should be read as hypothesis-generating, not practice-changing. (rmit.edu.au)
There are also important limitations and conflicts to keep in view. This was a six-dog pilot, not a large randomized field study, and the publicly accessible summaries do not establish comparative effectiveness against surgery or standard medical management. The ScienceDirect abstract notes that several authors hold shares in Snoretox Ltd., which heightens the need for independent replication. The company’s own site says the work has drawn conference interest, including acceptance at ACVIM Forum in Seattle in June 2026 and the ECVS Annual Scientific Meeting in Liverpool in July 2026, but conference visibility is not the same as broad clinical validation. (sciencedirect.com)
Why it matters: For veterinary teams, Snoretox-1 is notable because it points toward a new therapeutic lane in BOAS: targeted neuromuscular support. If that mechanism holds up in larger studies, it could create another option for dogs that are poor anesthesia candidates, for pet parents hesitant about surgery, or for patients with incomplete response after standard procedures. It could also push BOAS management toward a more stratified model, where grading, body condition, prior surgery status, and functional response help determine whether a dog is best served by surgery, injection, combined treatment, or ongoing conservative management. But right now, the evidence supports curiosity and caution, not routine adoption. (vet.cam.ac.uk)
Expert reaction in the form of outside commentary was limited at the time of writing, but the broader professional context is clear: veterinary and welfare groups have spent years warning against normalizing brachycephalic respiratory compromise. That backdrop may make clinicians receptive to innovation, while also making them appropriately skeptical of small, company-linked datasets. In other words, the unmet need is real, and so is the bar for evidence. (bva.co.uk)
What to watch: Watch for full-text scrutiny of the paper, data from a larger field study, conference presentations in June and July 2026, and any regulatory developments that clarify whether Snoretox-1 can move from pilot-stage promise to a clinically available BOAS therapy. (snoretox.com)